Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma ( (ASND) ) just unveiled an announcement.
On October 22, 2025, Ascendis Pharma announced the commercial availability of SKYTROFA (TransCon hGH) in the United States, expanding its dosing options for adults with growth hormone deficiency. This development marks a significant step in the company’s efforts to enhance its product offerings in the endocrinology market, potentially improving its competitive positioning and providing more options for patients and healthcare providers.
The most recent analyst rating on (ASND) stock is a Buy with a $242.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock score is driven by strong earnings call highlights and positive technical indicators. However, financial performance and valuation concerns due to ongoing losses and reliance on debt financing weigh down the overall score.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, specializing in the development of therapies for unmet medical needs. The company focuses on endocrinology and rare diseases, with a significant emphasis on creating innovative treatments using its proprietary TransCon technology.
Average Trading Volume: 479,698
Technical Sentiment Signal: Buy
Current Market Cap: $12.43B
For an in-depth examination of ASND stock, go to TipRanks’ Overview page.